The FDA’s Quiet Signal: Why Drug Discovery Is Becoming a Data Business
Introduction
Everyone saw the headline on April 10th, 2025: The FDA wants to reduce animal testing.
But that’s not the real story. The real story is what replaces it.
The FDA is signaling a shift toward human-relevant data, including organoids, microphysiological systems, real-world evidence, and computational models.
A Shift That Triggers a Chain Reaction
This shift does not flip the industry overnight. But it triggers a chain reaction.
When animal models begin to fade from the center of preclinical safety testing, data becomes the bottleneck.
Not molecules. Not models. Data.
The key questions become:
- Who can generate it?
- Who can validate it?
- Who can learn from it at scale?
Drug Discovery Is Becoming a Data Infrastructure Problem
Increasingly, drug discovery is not won by the best molecule. It is won by the best data infrastructure.
The companies gaining advantage today are not simply discovering drugs. They are building data platforms that allow discovery to happen at scale.
As human-relevant experimental systems grow, including organoids, tissue models, real-world clinical data, and computational simulations, the amount of biological information expands rapidly.
And with that expansion comes complexity.
More Human Data Means More Complexity
More human data means more biological signal, but also more noise, more variability, and more relationships that need to be tracked and interpreted.
This shifts competitive advantage toward organizations that can manage that complexity.
Organizations that build systems capable of:
- generating large, high-quality datasets
- making that data findable and reusable
- connecting experimental results across time and teams
- preserving institutional knowledge
- tracing decisions and evidence
- making discovery reproducible
The Companies That Win Will Run Better Data Engines
In this environment, the companies that succeed will not simply run better pipelines.
They will run better data engines.
Drug discovery is increasingly shaped not just by new molecules, but by the systems that generate, organize, and validate evidence.
As regulatory frameworks evolve, those systems will become even more central to how therapies move from hypothesis to human.
About Informatics Insight
This article is adapted from a video originally published on YouTube as part of Informatics Insight, a series hosted by Bridge Informatics CEO Dan Ryder.
Click here to watch the original video and follow the series on the Bridge Informatics YouTube channel.